Last $7.39 USD
Change Today +0.02 / 0.27%
Volume 24.1K
EVAR On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GM
As of 10:15 AM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

lombard medical inc (EVAR) Snapshot

Open
$7.40
Previous Close
$7.37
Day High
$7.40
Day Low
$7.39
52 Week High
04/25/14 - $11.34
52 Week Low
08/14/14 - $5.31
Market Cap
119.6M
Average Volume 10 Days
14.4K
EPS TTM
--
Shares Outstanding
16.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LOMBARD MEDICAL INC (EVAR)

Related News

No related news articles were found.

lombard medical inc (EVAR) Related Businessweek News

No Related Businessweek News Found

lombard medical inc (EVAR) Details

Lombard Medical, Inc., a medical technology company, develops, manufactures, and markets endovascular stent-grafts for the repair of aortic aneurysms in the United States, the United Kingdom, Germany, and internationally. The company’s principal product is Aorfix, which is an endovascular stent-graft for the treatment of an abdominal aortic aneurysm with angulation at the neck of the aneurysm of up to 90 degrees. It is also developing stent-graft system to treat thoracic aortic aneurysms. Lombard Medical sells its products directly through its direct sales force and third-party distributors. The company was founded in 2000 and is based in Didcot, United Kingdom.

lombard medical inc (EVAR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

lombard medical inc (EVAR) Key Developments

Lombard Medical, Inc. Announces First Two Post Approval Procedures Using Lombard Medical's Aorfix

Lombard Medical, Inc. announced that the first two post approval procedures using Lombard Medical's Aorfix(TM) endovascular stent graft were performed in Japan. Aorfix received approval from the Japanese Ministry of Health, Labour and Welfare in August, and is the first and only endovascular stent graft with worldwide regulatory approvals for the treatment of patients with aortic neck angulations up to 90 degrees.

Lombard Medical, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Provides Revenue Guidance for 2014

Lombard Medical, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenue of $2,193,000 against $1,846,000 a year ago. Operating loss was $11,361,000 against $4,618,000 a year ago. Loss before taxation was $11,294,000 against $4,924,000 a year ago. Loss for the period was $11,072,000 against $4,692,000 a year ago. Basic and diluted loss per ordinary share from continuing operations was 85.5 cents against 57.9 cents a year ago. For the six months, the company reported revenue of $4,251,000 against $3,098,000 a year ago. Operating loss was $18,494,000 against $7,478,000 a year ago. Loss before taxation was $18,400,000 against $7,875,000 a year ago. Loss for the period was $17,991,000 against $7,643,000 a year ago. Basic and diluted loss per ordinary share from continuing operations was 149.1cents against 113.7 cents a year ago. Net cash outflow from operating activities was $16,406,000 against $6,167,000 a year ago. Purchase of property, plant and equipment were $1,158,000 against $785,000 a year ago. Purchase of intangible assets was $245,000. For 2014, the company expects to achieve revenue of between $12 million and $14 million, representing growth of between 72% to 101%, over the prior year.

Lombard Medical, Inc.'s Aorfix Receives Regulatory Approval in Japan for Treatment of Abdominal Aortic Aneurysms

Lombard Medical, Inc. announced that its lead product, Aorfix, an endovascular stent graft to treat AAA, has received approval from the Japanese Ministry of Health, Labour and Welfare. Commercial sales will follow reimbursement approval, which the Company anticipates receiving in September. Aorfix will be exclusively distributed by Medico's Hirata Inc., one of Japan's leading suppliers of vascular products with proven expertise in building significant market share for AAA stent grafts. Aorfix is the first and only endovascular stent graft approved in Japan to treat AAA in patients with aortic neck angulations up to 90 degrees, commonly considered to be challenging cases. Aorfix is currently approved to treat patients with neck angles up to 90 degrees in the US and Europe. The EVAR market in Japan is estimated at $140 million or 10% of the global market in 2013, and has been growing at an average rate of 18% over the last five years. In Japan, there are approximately 400 physicians at 200 clinics performing EVAR and it is estimated that approximately 55% of Japanese AAA patients are treated using this method.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVAR:US $7.39 USD +0.02

EVAR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $12.34 USD -0.07
CR Bard Inc $146.26 USD -0.97
Endologix Inc $13.82 USD -0.22
Medtronic Inc $65.79 USD -0.43
TriVascular Technologies Inc $13.88 USD +0.07
View Industry Companies
 

Industry Analysis

EVAR

Industry Average

Valuation EVAR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.8x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LOMBARD MEDICAL INC, please visit www.lombardmedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.